-
公开(公告)号：US20230302135A1
公开(公告)日：2023-09-28
申请号：US18042263
申请日：2021-08-25
发明人： Young-Wook WON , Byeong-Hyun CHA , David A. BULL
IPC分类号： A61K39/00 , C07K14/715 , C07K14/71 , C07K14/705 , C12N5/077
CPC分类号： A61K39/4637 , C07K14/7158 , C07K14/71 , C07K14/70517 , C12N5/0657 , C07K2319/03 , C12N2501/21 , C12N2501/06 , C12N2506/1353
摘要： Described herein are mesenchymal stem cells (MCS) expressing hybrid allosteric receptors (HAR) that are responsive to stromal cell-derived factor 1 alpha (SDF-1α) secreted from acutely infarcted myocardium. Binding of SDF-1α to CXCR4 activates the co-stimulatory signals, bone morphogenetic protein 2 type II receptor (BMP2R2) and BMP type I receptor (ALK3), in order to accelerate the differentiation into cardiomyocytes. HAR-MSC CXCR4 differentiates into cardiomyocytes through Smad1/5 phosphorylation induced by the BMP2 signaling. In acute myocardial infarction (AMI) models, HAR-MSC CXCR4 treatment leads to the functional improvements by facilitated differentiation and increased cytokine secretion. HAR-MSC CXCR4 cells can be used for the treatment of AMI.
-
2.发明申请公开(公告)号：US20180224434A9
公开(公告)日：2018-08-09
申请号：US15440826
申请日：2017-02-23
申请人： The Children's Medical Center Corporation , The United States of America, As Represented by the Secretary, Department of Health & Human Servic
发明人： Anjana Rao , Mamta Tahiliani , Kian Peng Koh , Suneet Agarwal , Aravind Iyer
IPC分类号： G01N33/53 , G01N33/574 , C12N9/02
CPC分类号： C12Q1/6827 , C12N5/0018 , C12N5/0607 , C12N5/0637 , C12N5/0696 , C12N9/0071 , C12N15/873 , C12N2501/15 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/606 , C12N2501/70 , C12N2501/71 , C12N2501/999 , C12N2506/1307 , C12N2506/1353 , C12N2510/00 , C12Q1/26 , C12Q1/6806 , C12Q1/6869 , C12Q1/6886 , C12Q2600/154 , G01N33/5011 , G01N33/5308 , G01N33/57426 , G01N33/57484 , G01N33/57496 , G01N2500/00 , C12Q2537/164 , C12Q2522/10 , C12Q2521/531
摘要： Provided herein are methods and kits for measuring a level of a 5-hydroxymethylcytosine in a nucleotide sequence from a subject, wherein the subject is a subject having a cancer or suspected of having cancer.
-
公开(公告)号：US10034902B2
公开(公告)日：2018-07-31
申请号：US14380155
申请日：2013-02-21
发明人： Chaya Brodie , Shimon Slavin
IPC分类号： A61K35/30 , C12N5/079 , A61K35/28 , A61K35/50 , A61K35/51 , C12Q1/6876 , C12N15/113
CPC分类号： A61K35/30 , A61K35/28 , A61K35/50 , A61K35/51 , C12N5/0622 , C12N15/113 , C12N2310/141 , C12N2320/11 , C12N2330/10 , C12N2501/01 , C12N2501/11 , C12N2501/115 , C12N2501/135 , C12N2501/195 , C12N2501/41 , C12N2501/65 , C12N2502/13 , C12N2502/1305 , C12N2502/1311 , C12N2502/1317 , C12N2502/1323 , C12N2502/1329 , C12N2502/1335 , C12N2502/1341 , C12N2502/1347 , C12N2502/1352 , C12N2502/1358 , C12N2502/1364 , C12N2502/137 , C12N2502/1376 , C12N2502/1382 , C12N2502/1388 , C12N2502/1394 , C12N2506/025 , C12N2506/1353 , C12N2506/1369 , C12N2506/1384 , C12N2506/1392 , C12N2510/00 , C12Q1/6876 , C12Q2600/178
摘要： A method of generating a population of cells useful for treating a nerve disease or disorder in a subject, the method comprising up-regulating a level of at least one exogenous miRNA in mesenchymal stem cells (MSCs) and/or down-regulating a level of at least one miRNA using a polynucleotide agent that hybridizes to the miRNA, thereby generating the population of cells useful for treating the nerve disease or disorder. Isolated populations of cells with an astrocytic phenotype generated thereby and uses thereof are also provided.
-
公开(公告)号：US09963744B2
公开(公告)日：2018-05-08
申请号：US15108525
申请日：2014-12-30
申请人： DONGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION , KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE (KHIDI)
发明人： Gun-Il Im , Jong-Min Lee
CPC分类号： C12Q1/6883 , C12N5/0655 , C12N15/113 , C12N2310/14 , C12N2310/141 , C12N2310/531 , C12N2501/60 , C12N2501/65 , C12N2506/1353 , C12N2510/00 , C12Q2600/136 , C12Q2600/158 , C12Q2600/178
摘要： The present invention relates to a Krueppel-like factor 10 (KLF10) gene expression inhibitor promoting cartilage differentiation, and more specifically, to: a composition for promoting chondrocyte differentiation or treating cartilage diseases, containing a KLF10 gene expression inhibitor promoting cartilage differentiation and inhibiting the hypertrophy and dedifferentiation of chondrocytes; a cell therapeutic agent containing the composition; a method for promoting cartilage differentiation in bone marrow stem cells, comprising a step of expressing the composition in bone marrow stem cells; and a method for screening a chondrocyte differentiation promoter or a chondrocyte therapeutic agent. The present invention first examined the generation inhibition mechanism of indian hedgehog (IHH) protein of which the molecular biological mechanism has not yet been clearly examined, and ascertained that chondrocyte differentiation is promoted and chondrocyte hypertrophy is inhibited when chondrocyte differentiation is induced by expressing the KLF10 expression inhibitor in bone marrow stem cells. Therefore, the present invention has an advantage of enabling the use of bone marrow stem cells, which express a KLF10 expression inhibitor, as a chondrocyte therapeutic agent.
-
公开(公告)号：US20180044633A1
公开(公告)日：2018-02-15
申请号：US15722202
申请日：2017-10-02
申请人： The Children's Medical Center Corporation , The United States of America, As Represented by the Secretary, Department of Health & Human Servic
发明人： Anjana Rao , Mamta Tahiliani , Kian Peng Koh , Suneet Agarwal , Aravind Iyer
IPC分类号： C12N5/0783
CPC分类号： C12Q1/6827 , C12N5/0018 , C12N5/0607 , C12N5/0637 , C12N5/0696 , C12N9/0071 , C12N15/873 , C12N2501/15 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/606 , C12N2501/70 , C12N2501/71 , C12N2501/999 , C12N2506/1307 , C12N2506/1353 , C12N2510/00 , C12Q1/26 , C12Q1/6806 , C12Q1/6869 , C12Q1/6886 , C12Q2521/531 , C12Q2522/10 , C12Q2537/164 , C12Q2600/154 , G01N33/5011 , G01N33/5308 , G01N33/57426 , G01N33/57484 , G01N33/57496 , G01N2500/00
摘要： The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.
-
公开(公告)号：US09775879B2
公开(公告)日：2017-10-03
申请号：US14888343
申请日：2014-04-30
发明人： Je Sang Ko , Jeong-Han Kim
CPC分类号： A61K38/17 , C12N5/0653 , C12N2501/998 , C12N2506/1346 , C12N2506/1353 , C12Q1/686 , G01N33/502 , G01N2500/00 , G01N2500/10 , G01N2800/042 , G01N2800/044
摘要： The present invention relates to a use of a human small leucine zipper protein in the adipocyte differentiation procedure. More specifically, sLZIP binds with PPARγ2 to induce the formation of a complex of HDAC3 and PPARγ2, thereby functioning as a corepressor to negatively inhibit the transcriptional activity of PPARγ2 and suppress the differentiation to adipocytes, and thus can be used as a marker for treating diabetes and obesity and developing new medicines therefor.
-
公开(公告)号：US20170176420A1
公开(公告)日：2017-06-22
申请号：US15440319
申请日：2017-02-23
申请人： The Children's Medical Center Corporation , The United States of America, As Represented by the Secretary, Department of Health & Human Servic
发明人： Anjana Rao , Mamta Tahiliani , Kian Peng Koh , Suneet Agarwal , Aravind Iyer
IPC分类号： G01N33/53 , C12N5/074 , G01N33/574
CPC分类号： C12Q1/6827 , C12N5/0018 , C12N5/0607 , C12N5/0637 , C12N5/0696 , C12N9/0071 , C12N15/873 , C12N2501/15 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/606 , C12N2501/70 , C12N2501/71 , C12N2501/999 , C12N2506/1307 , C12N2506/1353 , C12N2510/00 , C12Q1/26 , C12Q1/6806 , C12Q1/6869 , C12Q1/6886 , C12Q2521/531 , C12Q2522/10 , C12Q2537/164 , C12Q2600/154 , G01N33/5011 , G01N33/5308 , G01N33/57426 , G01N33/57484 , G01N33/57496 , G01N2500/00
摘要： The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.
-
公开(公告)号：US20170175085A1
公开(公告)日：2017-06-22
申请号：US15440424
申请日：2017-02-23
申请人： The Children's Medical Center Corporation , The United States of America, As Represented by the Secretary, Department of Health & Human Servi
发明人： Anjana Rao , Mamta Tahiliani , Kian Peng Koh , Suneet Agarwal , Aravind Iyer
IPC分类号： C12N5/074 , G01N33/574 , G01N33/53
CPC分类号： C12Q1/6827 , C12N5/0018 , C12N5/0607 , C12N5/0637 , C12N5/0696 , C12N9/0071 , C12N15/873 , C12N2501/15 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/606 , C12N2501/70 , C12N2501/71 , C12N2501/999 , C12N2506/1307 , C12N2506/1353 , C12N2510/00 , C12Q1/26 , C12Q1/6806 , C12Q1/6869 , C12Q1/6886 , C12Q2521/531 , C12Q2522/10 , C12Q2537/164 , C12Q2600/154 , G01N33/5011 , G01N33/5308 , G01N33/57426 , G01N33/57484 , G01N33/57496 , G01N2500/00
摘要： The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.
-
公开(公告)号：US20170119931A1
公开(公告)日：2017-05-04
申请号：US15235466
申请日：2016-08-12
发明人： Treena L. Arinzeh , Norbert Weber , Michael Jaffe
IPC分类号： A61L27/38 , A61L27/16 , C12N5/0793 , C12N5/00
CPC分类号： A61L27/3895 , A61L27/16 , A61L27/383 , A61L27/3834 , A61L2400/12 , C12N5/0068 , C12N5/0619 , C12N2501/13 , C12N2506/1307 , C12N2506/1353 , C12N2533/30 , C08L27/16
摘要： Due to the size and complexity of tissues such as the spinal cord and articular cartilage, specialized constructs incorporating cells as well as smart materials may be a promising strategy for achieving functional recovery. Aspects of the present invention describe the use of an electroactive, or piezoelectric, material that will act as a scaffold for stem cell induced tissue repair. Embodiments of the inventive material can also act alone as an electroactive scaffold for repairing tissues. The piezoelectric material of the present invention acts as a highly sensitive mechanoelectrical transducer that will generate charges in response to minute vibrational forces.
-
公开(公告)号：US20170095511A1
公开(公告)日：2017-04-06
申请号：US15227831
申请日：2016-08-03
发明人： Xuhang LI , Xiaohua HOU , Rong LIN
IPC分类号： A61K35/28 , A61K9/00 , C12N5/0775
CPC分类号： A61K35/28 , A61K9/0053 , A61K2035/124 , C12N5/0619 , C12N5/0663 , C12N2501/13 , C12N2506/1353
摘要： Disclosed is a composition including: an isolated in vitro pre-conditioned population of adult bone marrow derived mesenchymal stem cells (BMSCs), wherein the BMSCs express neuronal markers, and wherein the neuronal markers are PGP9.5, NSE, Tuj1, HuC/D and neuronal nitric oxide synthase (nNOS). Methods of preparing the BMSCs are also provided. In addition, the present disclosure is directed to a method of treating an enteric nervous system-related disorder including: administering to a subject in need thereof a pharmaceutical composition including the in vitro pre-conditioned BMSC population and a pharmaceutically acceptable carrier.
-
-
-
-
-
-
-
-
-
搜索结果
339 条记录 (耗时 0.068 秒)
